Guerbet: Guerbet Strengthens Its Executive Committee With Two New Appointments to Accelerate Its Commercial and Industrial Development
Guerbet: Guerbet Strengthens Its Executive Committee With Two New Appointments to Accelerate Its Commercial and Industrial Development
Guerbet strengthens its Executive Committee with two new appointments to accelerate its commercial and industrial development
加柏通過兩項新任命加強其執行委員會，以加速其商業和工業發展
- Dan Raffi appointed Director of Commercial Operations
- Raoul Bernhardt appointed Director of Industrial Operations
- 丹·拉菲被任命爲商業運營董事
- 拉烏爾·伯恩哈特被任命爲工業運營董事
Villepinte, 10 July 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the strengthening of its management team with two appointments. Dan Raffi and Raoul Bernhardt have joined the Group as Director of Commercial Operations and Director of Industrial Operations respectively. They will both become members of Guerbet's Executive Committee
維勒班特，2023 年 7 月 10 日: 醫學成像造影劑和解決方案領域的全球專家加柏公司（FR0000032526 GBT）宣佈通過兩次任命加強其管理團隊。Dan Raffi 和 Raoul Bernhardt 分別加入集團，董事商業運營總監和工業運營總監。他們都將成爲加柏執行委員會的成員
Dan RAFFI - Director of Commercial Operations
Dan RAFFI-商業運營董事
Raoul Bernhardt - Director of Industrial Operations
Raoul Bernhardt-工業運營董事
Guerbet's Executive Committee now has 9 members:
加柏執行委員會現在有9名成員：
- David Hale, Chief Executive Officer
- Charlotte Bamière, Director of Legal Affairs
- Raoul Bernhardt, Director of Industrial Operations
- Philippe Bourrinet, Director of Development, Medical & Regulatory Affairs, and Group Chief Pharmacist
- Valérie Brissart, Director of Diagnostic Imaging
- Jérôme Estampes, Chief Financial Officer and Senior VP Business Development and Licensing
- Leïla Mechaï, Director of Human Resources and Corporate Social Responsibility
- François Nicolas, Director of R&D, R&I and Chief Digital Officer
- Dan Raffi, Director of Commercial Operations
- 大衛·黑爾，首席執行官
- 夏洛特·巴米爾，法律事務董事
- 拉烏爾·伯恩哈特，工業運營董事
- Philippe Bourrinet，開發、醫療和監管事務董事監兼集團首席藥劑師
- Valerie Brissart，診斷成像董事
- Je'rome Estampes，首席財務官兼業務發展和許可高級副總裁
- Leiüla Mechai，人力資源和企業社會責任董事
- Francois Nicolas，研發、研發總董事兼首席數字官
- 丹·拉菲，商業運營董事
Upcoming events:
即將舉行的活動：
Publication of first-half annual revenue
20 July 2023 after trading
公佈上半年年收入
2023 年 7 月 20 日交易結束後
About Guerbet
關於加柏公司
At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a world leader in medical imaging, offering a complete range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. Pioneers in contrast media for 95 years, with more than 2,830 employees worldwide, we are constantly innovating and devote 8% to 10% of our revenue to research and development in five centres in France, Israel, and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €753 million in revenue in 2022. For more information, please visit .
在加柏公司，我們建立了持久的關係，使人們能夠過上更好的生活。這就是我們的目的。我們是醫學成像領域的全球領導者，爲診斷和介入成像提供全套藥品、醫療器械以及數字和人工智能解決方案。95 年來，我們一直是對比媒體的先驅，在全球擁有 2,830 多名員工，我們不斷創新，將收入的8％至10％用於法國、以色列和美國的五個中心的研發。加柏集團（GBT）在巴黎泛歐交易所（B板塊——中型股）上市，2022年創造了7.53億歐元的收入。欲了解更多信息，請訪問 。
Attachment
附件
- 2023 07 10 - GUERBET - Appointments in Executive Committee
- 2023 07 10-GUERBET-執行委員會成員任命
譯文內容由第三人軟體翻譯。